Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod.
Launched by SEOUL ST. MARY'S HOSPITAL · Jun 29, 2017
Trial Information
Current as of May 30, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Able and willing to comply with all study procedures and voluntarily signs informed consent form.
- • Female subjects age 19-50 years.
- • HPV 16 and/or 18 positive.
- • Colposcopy is satisfactory based on visualization of the entire squamocolumnar junction and the upper limit of the entire aceto-white or suspected CIN disease area
- • Histopathologically diagnosed with Cervical Intraepithelial Neoplasia 3, CIN 3.
- Exclusion Criteria:
- • Pregnancy or breastfeeding
- • History of previous therapeutic HPV vaccination (individuals who have been immunized with licensed prophylactic HPV vaccines are not excluded).
- • Positive serological test for hepatitis C virus or hepatitis B virus surface antigen (HBsAg) or human immunodeficiency virus (HIV).
- • Any other ineligible condition at the discretion of the investigator that would be ineligible to participate the study.
About Seoul St. Mary's Hospital
Seoul St. Mary's Hospital, a leading healthcare institution in South Korea, is dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. Affiliated with the Catholic University of Korea, the hospital combines state-of-the-art facilities with a commitment to high-quality patient care and ethical research practices. With a multidisciplinary team of experienced researchers and clinicians, Seoul St. Mary's Hospital actively participates in a wide range of clinical studies, focusing on diverse therapeutic areas to contribute valuable insights to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials